Patient-specific HLA-I subtypes predict response to immune checkpoint blockade by Kyrillus S. Shohdy, Jack Atherton, Jessica Longland, Jennifer Alison, Manon Pillai, Fiona Thistlethwaite

Get full text

A single centre experience of patients with rare cancers referred for early phase clinical trials by Angelos Angelakas, Natalie Cook, Donna M. Graham, Matthew Krebs, Fiona Thistlethwaite, Louise Carter

Get full text

Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public rep... by Cindy Cooper, Katie Biggs, Alexander Rothman, Christina Yap, Fiona Thistlethwaite, Della Ogunleye, Munyaradzi Dimairo, Robin Chatters, Shamila Ditta, Jonathan Woodward

Get full text

Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients by Julio Herrero Colomina, Eleanor Johnston, Kate Duffus, Zoulikha M. Zaïr, Fiona Thistlethwaite, Matthew Krebs, Louise Carter, Donna Graham, Natalie Cook

Get full text

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

Get full text